{"groups":[{"description":"Participants received 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.","id":"FG000","title":"Part 1: Cohort A: METex14 Skipping Alterations"},{"description":"Participants received 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.","id":"FG001","title":"Part 1: Cohort B: MET Amplification"},{"description":"Participants received 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.","id":"FG002","title":"Part 2: Cohort C: Confirmatory Part for METex14 Skipping Alterations"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"33"}],"type":"still on treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"152"},{"groupId":"FG001","numSubjects":"24"},{"groupId":"FG002","numSubjects":"161"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"137"},{"groupId":"FG001","numSubjects":"23"},{"groupId":"FG002","numSubjects":"128"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"33"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"For Cohort A: A total of 168 participants were screened of which 152 participants were enrolled to receive the study drug. For Cohort B: A total of 32 participants were screened of which 24 participants were enrolled to receive the study drug. For Cohort C: A total of 175 participants were screened of which 161 participants were enrolled to receive the study drug."}